Insulin Action in the Islet β-Cell

  • Rohit N. Kulkarni


The techniques that allow spatio-temporal control of gene deletion or gene expression in transgenic and knockout animals have been useful to directly evaluate the roles of the insulin and IGF-1 receptors and proteins in their signaling pathway in islet cells. While a functional role for insulin signaling in islet β-cells is now well established, the precise pathways and proteins that mediate β-cell growth and function during development and adulthood are continuing to be unraveled. This chapter will focus on recent studies derived from using transgenic, knockout and siRNA techniques to directly examine the role of insulin and IGF-I in the regulation of development, growth and function of islet β-cells.


Insulin Secretion Beta Cell Insulin Receptor Insulin Receptor Substrate Placental Lactogen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blakesley VA, Butler AA, Koval AP et al. In: Rosenfeld R, Roberts Jr C, eds. The IGF system. 1999:143–164.Google Scholar
  2. 2.
    Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995; 16:117–142.PubMedGoogle Scholar
  3. 3.
    De Meyts P et al. The insulin-like growth factor-1 receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994; 42:152–169.PubMedGoogle Scholar
  4. 4.
    Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414:788–791.PubMedGoogle Scholar
  5. 5.
    Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799–806.PubMedGoogle Scholar
  6. 6.
    Kahn CR. Diabetogenes and the cause of type II diabetes (Banting Lecture). Diabetes 1994; 1066–1084.Google Scholar
  7. 7.
    White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283:E413–E422.PubMedGoogle Scholar
  8. 8.
    Accili D. Lilly lecture 2003. The struggle for mastery in insulin action: From triumvirate to republic. Diabetes 2004; 53(7): 1633–42.PubMedGoogle Scholar
  9. 9.
    White MF, Yenush L. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol 1998; 228:179–208.PubMedGoogle Scholar
  10. 10.
    Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103:931–943.PubMedGoogle Scholar
  11. 11.
    DeFronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 1988; 37:667–687.Google Scholar
  12. 12.
    Kulkarni RN. Receptors for insulin and insulin-like growth factor-1 and insulin receptor substrate-1 mediate pathways that regulate islet function. Biochem Soc Trans 2002; 30:317–322.PubMedGoogle Scholar
  13. 13.
    Leibowitz G et al. Insulin does not mediate glucose stimulation of proinsulin biosynthesis. Diabetes 2003; 52:998–1003.PubMedGoogle Scholar
  14. 14.
    Wicksteed B, Alarcon C, Briaud I et al. Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet beta-cells but not regulated via a positive feedback of secreted insulin. J Biol Chem 2003; 278:42080–42090.PubMedGoogle Scholar
  15. 15.
    Irminger JC, Vollenweider FM, Neerman-Arbez M et al. Human proinsulin conversion in the regulated and the constitutive pathways of transfected AtT20 cells. J Biochem 1994; 269:1756–1762.Google Scholar
  16. 16.
    Halban PA. Proinsulin processing in the regulated and the constitutive secretory pathway. Diabetologia 1994; 37(Suppl 2):S65–S72.PubMedGoogle Scholar
  17. 17.
    Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-1 receptors. Endo Reviews 2001; 22:818–835.Google Scholar
  18. 18.
    Persaud SJ, AsareAnane H, Jones PM. Insulin receptor activation inhibits insulin secretion from human islets of Langerhans. Growth Regul 2002; 510:225–228.Google Scholar
  19. 19.
    Aspinwall CA, Lakey JRT, Kennedy RT. Insulin-stimulated insulin secretion in single pancreatic beta cells. The Journal of Biological Chemistry 1998; 274:6360–6365.Google Scholar
  20. 20.
    Johnson JD, Misler S. Nicotinic acid-adenine dinucleotide phosphate-sensitive calcium stores initiate insulin signaling in human beta cells. Proc Natl Acad Sci USA 2002; 99:14566–14571.PubMedGoogle Scholar
  21. 21.
    Luciani DS, Johnson JD. Acute effects of insulin on beta-cells from transplantable human islets. Mol Cell Endocrinol 2005; 241:88–98.PubMedGoogle Scholar
  22. 22.
    Leibiger B, Leibiger IB, Moede T et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell 2001; 7:559–570.PubMedGoogle Scholar
  23. 23.
    Bouche C, Kulkarni RN, Kahn CR et al. Exogenous insulin enhances glucose-stimulated insulin secretion in healthy humans. Diabetes 54 2005, (Ref Type: Generic).Google Scholar
  24. 24.
    Rasouli N, Hale T, Kahn SE et al. Effects of short term experimental insulin resistance and family history of diabetes on pancreatic ta|-cell function in nondiabetic individuals. J Clin Endocrinol Metab 2005; 90(10):5825”78PubMedGoogle Scholar
  25. 24a.
    Gunton JE, Kulkarni RN, Yim S et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 2005; 122(3):337–49.PubMedGoogle Scholar
  26. 24b.
    Hribal ML, Perego L, Lovari S et al. Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. FASEB J 2003; 17(10):1340–2.PubMedGoogle Scholar
  27. 25.
    Pictet R, Rutter WJ. In: Steiner DF, Freinkel M, eds. Handbook of Physiology. Washington, DC: American Physiological Society, 1972:25–66.Google Scholar
  28. 26.
    Herrera PL. Defining the cell lineages of the islets of Langerhans using transgenic mice. Int J Dev Biol 2002; 46:97–103.PubMedGoogle Scholar
  29. 27.
    Murtaugh LC, Melton DA. Genes, signals, and lineages in pancreas development. Annu Rev Cell Dev Biol 2003; 19:71–89.PubMedGoogle Scholar
  30. 28.
    Sander M, German MS. The beta cell transcription factors and development of the pancreas. J Mol Med 1997; 75:327–340.PubMedGoogle Scholar
  31. 29.
    Habener JF, Kemp DM, Thomas MK. Minireview: Transcriptional regulation in pancreatic development. Endocrinology 2005; 146:1025–1034.PubMedGoogle Scholar
  32. 30.
    GuG, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002; 129:2447–2457.Google Scholar
  33. 31.
    Fowden AL, Hill DJ. Intra-uterine programming of the endocrine pancreas. Brit Med Bull 2001:123–142.Google Scholar
  34. 32.
    Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today 2003; 69:257–271.PubMedGoogle Scholar
  35. 33.
    Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res 1985; 19:879–886.PubMedGoogle Scholar
  36. 34.
    Milner RD, Hill DJ. Fetal growth control: The role of insulin and related peptides. Clin Endocrinol (Oxf.) 1984; 21:415–433.Google Scholar
  37. 35.
    Hill DJ. Development of the endocrine pancreas. Rev Endocr Metab Disord 2005; 6:229–238.PubMedGoogle Scholar
  38. 36.
    Hogg J, Han VKM, Clemmons DR et al. Interactions of glucose, insulin-like growth factors (IGFs) and IGF binding proteins in the regulation of DNA synthesis by isolated fetal rat islets of langerhans. J Endocrinol 1993:401–412.Google Scholar
  39. 37.
    Fehmann HC, Jehle P, Goke B. IGF-I and IGF-II: Expression and function in the endocrine pancreas. Exp Clin Endocrinol Diabetes 1995; 103(Suppl 2):37–41.PubMedGoogle Scholar
  40. 38.
    Hill DJ, Hogg J. Growth factor control of pancreatic B cell hyperplasia. Baillieres. Clin Endocrinol Metab 1991; 5:689–698.PubMedGoogle Scholar
  41. 39.
    Hill DJ, Petrik J, Arnay E. Growth factors and the regulation of fetal growth. Diabetes Care 1998; (Suppl 2):B60–B69.Google Scholar
  42. 40.
    Orban PC, Chui D, Marth JD. Tissue-and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci USA 1992; 89:6861–6865.PubMedGoogle Scholar
  43. 41.
    Ryding AD, Sharp MG, Mullins JJ. Conditional transgenic technologies. J Endocrinol 2001; 171:1–14.PubMedGoogle Scholar
  44. 42.
    Duvillie B et al. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology 2002; 143:1530–1537.PubMedGoogle Scholar
  45. 43.
    Duvillie B et al. Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci USA 1997; 94:5137–5140.PubMedGoogle Scholar
  46. 44.
    Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science 2001:1–10.Google Scholar
  47. 45.
    Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. Mech Dev 2003; 120:59–64.PubMedGoogle Scholar
  48. 46.
    Cleaver O, Melton DA. Endothelial signaling during development. Nat Med 2003; 9:661–668.PubMedGoogle Scholar
  49. 47.
    Lu Y et al. Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes 2004; 53:3131–3141.PubMedGoogle Scholar
  50. 48.
    Petrik J et al. Overexpression of insulin-like growth factor-II in transgenic mice is associated with pancreatic islet cell hyperplasia. Endocrinology 1999; 140:2353–2363.PubMedGoogle Scholar
  51. 49.
    Devedjian JC et al. Transgenic mice overexpressing insulin-like growth factor-II in B cells develop type 2 diabetes. J Clin Invest 2000; 105:731–740.PubMedGoogle Scholar
  52. 50.
    Efstratiadis A. Genetics of mouse growth. Int J Dev Biol 1998; 955–976.Google Scholar
  53. 51.
    Liu JP, Baker J, Perkins JA et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (lgf-1) and type 1 IGF receptor (lgf1r). Cell 1993; 75:59–72.PubMedGoogle Scholar
  54. 52.
    Powell-Braxton L et al. IGF-I is required for normal embryonic growth in mice. Genes & Development 1993; 7:2609–2617.Google Scholar
  55. 53.
    Woods KA, Camacho-Hubner C, Savage MO et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335:1363–1367.PubMedGoogle Scholar
  56. 54.
    Accili D et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996; 12:106–109.PubMedGoogle Scholar
  57. 55.
    Joshi RL et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15:1542–1547.PubMedGoogle Scholar
  58. 56.
    Joshi RL et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15:1542–1547.PubMedGoogle Scholar
  59. 57.
    Withers DJ et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391:900–904.PubMedGoogle Scholar
  60. 58.
    Kido Y, Nakae J, Xuan S et al. Beta cell development in mice lacking insulin and type I IGF receptors. Diabetes 2000; 49(Suppl 1).Google Scholar
  61. 59.
    Kulkarni RN et al. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in Type 2 diabetes. Cell 1999; 96:329–339.PubMedGoogle Scholar
  62. 60.
    Kulkarni RN et al. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 2002; 31:111–115.PubMedGoogle Scholar
  63. 61.
    Xuan S et al. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 2002; 110:1011–1019.PubMedGoogle Scholar
  64. 62.
    Otani K et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab 2004; 286:E41–E49.PubMedGoogle Scholar
  65. 63.
    Da Silva X, Qian Q, Cullen PJ et al. Distinct roles for insulin and insulin-like growth factor-1 receptors in pancreatic beta-cell glucose sensing revealed by RNA silencing. Biochem J 2004; 377:149–158.Google Scholar
  66. 64.
    Kulkarni RN, Kahn CR. Molecular basis of pancreas development and function. In: Habener JF, Hussain M, eds. New York City: Kluwer Academic Publishers, 2001:299–323.Google Scholar
  67. 65.
    Elders MJ et al. Endocrine-metabolic relationships in patients with leprechaunism. J Natl Med Assoc 1982; 74:1195–1210.PubMedGoogle Scholar
  68. 66.
    Taylor SI. Lilly Lecture: Molecular mechanisms of insulin resistance-Lessons from patients with mutations in the insulin receptor gene. Diabetes 1992; 41:1473–1490.PubMedGoogle Scholar
  69. 67.
    Araki E et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372:186–190.PubMedGoogle Scholar
  70. 68.
    Tamemoto H et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372:182–186.PubMedGoogle Scholar
  71. 69.
    Kulkarni RN et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest 1999; 104:R69–R75.PubMedGoogle Scholar
  72. 70.
    Kubota N et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 2000; 49:1880–1889.PubMedGoogle Scholar
  73. 71.
    Aspinwall CA et al. Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca2+ stores in insulin-stimulated insulin secretion in beta-cells. J Biol Chem 2000; 275:22331–22338.PubMedGoogle Scholar
  74. 72.
    Kulkarni RN, Roper M, Dahlgren Insulin secretory defect in IRS-1 null mice is linked with reduced calcium signaling and altered expression of SERCA-2b and-3. Diabetes 2004; 53:1517–1525.PubMedGoogle Scholar
  75. 73.
    Hennige AM et al. Alterations in growth and apoptosis of insulin receptor substrate-1 deficient beta-cells. Am J Physiol Endocrinol Metab 2005; 289:E337–E346.PubMedGoogle Scholar
  76. 74.
    Hennige AM et al. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 2003; 112:1521–1532.PubMedGoogle Scholar
  77. 75.
    Lin X et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114:908–916.PubMedGoogle Scholar
  78. 76.
    Kubota N et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114:917–927.PubMedGoogle Scholar
  79. 77.
    Choudhury AI The role of insulin receptor substrate 2 in hypothalamic and beta-cell function. Journal of Clinical Investigation 2005; 115:940–950.PubMedGoogle Scholar
  80. 78.
    Jhala US et al. cAMP promotes pancreatic beta cell survival via CREB mediated induction of IRS2. Genes and Development 2003; 17:1575–1580.PubMedGoogle Scholar
  81. 79.
    Lingohr MK et al. Decreasing IRS-2 expression in pancreatic beta-cels (INS-1) promotes apoptosis, which can be compensated for by introduction of IRS-4 expression. Mol Cell Endocrinol 2003; 209:17–31.PubMedGoogle Scholar
  82. 80.
    Briaud I et al. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback downregulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005; 280:2282–2293.PubMedGoogle Scholar
  83. 81.
    Kushner JA et al. Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes 2004; 53:61–66.PubMedGoogle Scholar
  84. 82.
    Kushner JA et al. Pdx1 restores beta cell function in Irs2 knockout mice. J Clin Invest 2002; 109:1193–1201.PubMedGoogle Scholar
  85. 83.
    Kushner JA et al. Pten regulation of islet growth and glucose homeostasis. J Biol Chem 2005.Google Scholar
  86. 84.
    Liu SC, Wang Q, Lienhard GE et al. Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J Biol Chem 1999; 274:18093–18099.PubMedGoogle Scholar
  87. 85.
    Fantin VR, Wang GE, Lienhard GE et al. Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homostasis. Am. J Physiol 2000; 278:E127–133.Google Scholar
  88. 86.
    Ueki K et al. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2002; 99:419–424.PubMedGoogle Scholar
  89. 87.
    Terauchi Y et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 1999; 21:230–235.PubMedGoogle Scholar
  90. 88.
    Mauvais-Jarvis F et al. Reduced expression of the murine p85a subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 2002; 109:141–149.PubMedGoogle Scholar
  91. 89.
    Eto K et al. Phosphatidylinositol 3-kinase suppresses glucose-stimulated insulin secretion by affecting post-cytosolic [Ca(2+)] elevation signals. Diabetes 2002; 51:87–97.PubMedGoogle Scholar
  92. 90.
    Zawalich WS, Tesz GJ, Zawalich KC. Inhibitors of phosphatidylinositol 3-kinase amplify insulin release from islets of lean but not obse mice. J Endocrinol 2002; 174:247–258.PubMedGoogle Scholar
  93. 91.
    Zawalich WS, Zawalich KC. A link between insulin resistance and hyperinsulinemia: Inhibitors of phosphatidylinositol 3-kinase augment flucose-induced insulin secretion from islets of lean, but not obese, rats. Endocrinology 2000; 141:3287–3295.PubMedGoogle Scholar
  94. 92.
    Liu Y et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol 2005; 12:99–107.PubMedGoogle Scholar
  95. 93.
    Cho H et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 2001; 292:1728–1731.PubMedGoogle Scholar
  96. 94.
    Tuttle RL et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med 2001; 7:1133–1137.PubMedGoogle Scholar
  97. 95.
    Bernal-Mizrachi E, Wen W, Stahlhut S et al. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 2001; 108:1631–1638.PubMedGoogle Scholar
  98. 96.
    Bernal-Mizrachi E et al. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J Clin Invest 2004; 114:928–936.PubMedGoogle Scholar
  99. 97.
    Pende M et al. Hypoinsulinaemia,glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000; 408:994–997.PubMedGoogle Scholar
  100. 98.
    Bonner-Weir S, Smith FE. Islet cell growth and the growth factors involved. TEM 1994; 5:60–64.Google Scholar
  101. 99.
    Bonner-Weir S. Regulation of pancreatic β-cell mass in vivo. Recent Prog Horm Res 1994; 49:91–104.PubMedGoogle Scholar
  102. 100.
    Vasavada RC et al. Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem 2000; 275:15399–15406.PubMedGoogle Scholar
  103. 101.
    Vasavada RC et al. Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. J Biol Chem 1996; 271:1200–1208.PubMedGoogle Scholar
  104. 102.
    Garcia-Ocana A et al. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem 2000; 275:1226–1232.PubMedGoogle Scholar
  105. 103.
    Dai C, Huh CG, Thorgeirsson SS et al. Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am J Pathol 2005; 167:429–436.PubMedGoogle Scholar
  106. 104.
    Roccisana J et al. Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass. Diabetes 2005; 54:2090–2102.PubMedGoogle Scholar
  107. 105.
    Fujinaka Y, Sipula D, Garcia-Ocana A et al. Characterization of mice doubly transgenic for parathyroid hormone-related protein and murine placental lactogen: A novel role for placental lactogen in pancreatic beta-cell survival. Diabetes 2004; 53:3120–3130.PubMedGoogle Scholar
  108. 106.
    Bonner-Weir S et al. In vitro cultivation of human islets from expanded ductal tissue. Proc Natl Acad Sci USA 2000; 97:7999–8004.PubMedGoogle Scholar
  109. 107.
    Suarez-Pinzon WL, Lakey JR, Brand SJ et al. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet ta-cells from pancreatic duct cells and an increase in functional ta-cell mass*. J Clin Endocrinol Metab 2005.Google Scholar
  110. 108.
    Yoon KH et al. Selective beta-Cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in korea. J Clin Endocrinol Metab 2003; 88:2300–2308.PubMedGoogle Scholar
  111. 109.
    Butler AE et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102–110.PubMedGoogle Scholar
  112. 110.
    Dor Y, Brown J, Martinez OI et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004; 429:41–46.PubMedGoogle Scholar
  113. 111.
    Gershengorn MC et al. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 2004; 306:2261–2264.PubMedGoogle Scholar
  114. 112.
    Lechner A, Nolan AL, Blacken RA et al. Redifferentiation of insulin-secreting cells after in vitro expansion of adult human pancreatic islet tissue. Biochem Biophys Res Commun 2005; 327:581–588.PubMedGoogle Scholar
  115. 113.
    Rane SG et al. Loss of cyclin-dependent kinase (Cdk4) expression causes insulin-deficient diabetes and cdk4 activation results in β-islet cell hyperplasia. Nat Genet 1999; 22:44–52.PubMedGoogle Scholar
  116. 114.
    Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest 2004; 114:963–968.PubMedGoogle Scholar
  117. 115.
    Kushner JA, Ciemerych MA, Sicinska E et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 2005; 25:3752–3762.PubMedGoogle Scholar
  118. 116.
    Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15:740–746.PubMedGoogle Scholar
  119. 117.
    Potter E, Bergwitz C, Brabant G. The cadherin-catenin system: Implications for growth and differentiation of endocrine tissues. Endocr Rev 1999; 20:207–239.PubMedGoogle Scholar
  120. 118.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442–454.PubMedGoogle Scholar
  121. 119.
    Savagner P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bio Essays 2001; 23:912–923.Google Scholar
  122. 120.
    Morali OG et al. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001; 20:4942–4950.PubMedGoogle Scholar
  123. 121.
    Kang Y, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004; 118:277–279.PubMedGoogle Scholar
  124. 122.
    El Bahrawy MA, Pignatelli M. E-cadherin and catenins: Molecules with versatile roles in normal and neoplastic epithelial cell biology. Microsc Res Tech 1998; 43:224–232.PubMedGoogle Scholar
  125. 123.
    Dahl U, Sjodin A, Semb H. Cadherins regulate aggregation of pancreatic beta-cells in vivo. Development 1996; 122:2895–2902.PubMedGoogle Scholar
  126. 124.
    Kulkarni RN et al. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 2004; 114:828–836.PubMedGoogle Scholar
  127. 125.
    Kitamura T et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002; 110:1839–1847.PubMedGoogle Scholar
  128. 126.
    Bonner-Weir S, Scaglia L, Montana E et al. Diabetes 1994. In: Baba S, Kaneko T, eds. Excerta Medica International Congress, 1995:179–228.Google Scholar
  129. 127.
    Accili D. A kinase in the life of the beta cell. J Clin Invest. 2001; 108:1575–1576.PubMedGoogle Scholar
  130. 128.
    Rabinovitch A, Quigley C, Russell T et al. Insulin and multiplication stimulating activity (and insulin-like growth factor) stimulate islet beta-cell replication in neonatal rat pancreatic monolayer cultures. Diabetes 1982:160–164.Google Scholar
  131. 129.
    McEvoy RC, Schmitt RV, Hegre OD. Syngeneic transplantation of fetal rat pancreas. I. Effect of insulin treatment of the reversal of alloxan diabetes. Diabetes 1978; 27:982–987.PubMedGoogle Scholar
  132. 130.
    Movassat J, Saulnier C, Portha B. Insulin administration enhances growth of the beta-cell mass in streptozotocin-treated newborn rats. Diabetes 1997; 46:1445–1452.PubMedGoogle Scholar
  133. 131.
    Ohsugi M et al. Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion. J Biol Chem 2005; 280:4992–5003.PubMedGoogle Scholar
  134. 132.
    Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci USA 2001; 98:7475–7480.PubMedGoogle Scholar
  135. 133.
    Bonner-Weir S, Deery D, Leahy JL et al. Compensatory growth of pancreatic β-cells in adult rats after short-term glucose infusion. Diabetes 1989; 38:49–53.PubMedGoogle Scholar
  136. 134.
    Stoffers DA. The development of beta-cell mass: Recent progress and potential role of GLP-1. Horm Metab Res 2004; 36:811–821.PubMedGoogle Scholar
  137. 135.
    Song KH et al. In vitro transdifferentiation of adult pancreatic acinar cells into insulin-expressing cells. Biochem Biophys Res Commun 2004; 316:1094–1100.PubMedGoogle Scholar
  138. 136.
    Paris M, Tourrel-Cuzin C, Plachot C et al. Review: Pancreatic beta-cell neogenesis revisited. Exp Diabesity Res 2004; 5:111–121.PubMedGoogle Scholar
  139. 137.
    Ferber S et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nature Medicine 2000; 6:568–572.PubMedGoogle Scholar
  140. 138.
    Kojima H et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 2003; 9:596–603.PubMedGoogle Scholar
  141. 139.
    Kaneko K et al. Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Diabetes Res Clin Pract 1999; 44:83–92.PubMedGoogle Scholar
  142. 140.
    Van Schravendijk CF, Foriers A, Van den Brande JL et al. Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells Endocrinology 1987; 121:1784–1788.PubMedGoogle Scholar
  143. 141.
    Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28:574–578.PubMedGoogle Scholar
  144. 142.
    Harvel PJ, Veith RC, Dunning BE et al. Role for autonomic nervous system to increase pancreatic glucagon secretion durning marked insulin-induced hypoglycemia in dogs. Diabetes 1991; 40:1107–1114.Google Scholar
  145. 143.
    Cryer PE. Banting Lecture. Hypoglycemia: The limiting factor in the management of IDDM. Diabetes 1994; 43:1378–1389.PubMedGoogle Scholar
  146. 144.
    Diao J, Asghar Z, Chan CB et al. Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells. J Biol Chem 2005; 280:33487–33496.PubMedGoogle Scholar
  147. 145.
    Sloop KW et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113:1571–1581.PubMedGoogle Scholar
  148. 146.
    Duncan SA, Navas MA, Dufort D et al. Regulation of a transcription factor network required for differentiation and metabolism. Science 1998; 281:692–695.PubMedGoogle Scholar
  149. 147.
    Odom DT et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303:1378–1381.PubMedGoogle Scholar
  150. 148.
    Postic C et al. Dual roles for glucokinase in flucose homeostasis as determined by liver and pancreatic × cell-specific gene knock-outs using cre recombinase. The Journal of Biological Chemistry 1998:1–11.Google Scholar
  151. 149.
    Scharf JG, Ramadori G, Braulke T et al. Cellular localization and hormonal regulation of biosynthesis of insulin-like growth factor binding proteins and of the acid-labile subunit within rat liver. Prog Growth Factor Res 1995; 6:175–180.PubMedGoogle Scholar
  152. 150.
    Funakoshi H, Nakamura T. Hepatocyte growth factor: From diagnosis to clinical applications. Clin Chim. Acta 2003; 327:1–23.PubMedGoogle Scholar
  153. 151.
    Michael MD et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6:87–97.PubMedGoogle Scholar
  154. 152.
    Wolfrum C, Besser D, Luca E et al. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci USA 2003; 100:11624–11629.PubMedGoogle Scholar
  155. 153.
    Kulkarni RN, Kahn CR. Molecular biology. HNFs—linking the liver and pancreatic islets in diabetes. Science 2004; 303:1311–1312.PubMedGoogle Scholar
  156. 154.
    Duvillie B et al. Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci USA 1997; 94:5137–5140.PubMedGoogle Scholar
  157. 155.
    Liu JP, Baker J, Perkins AS et al. Mice carrying null mutations of the genes encoding insulin-like growth factor (Igf-1) and type 1 IGF receptor (Igflr). Cell 1993; 75:59–72.PubMedGoogle Scholar
  158. 156.
    Accili D et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996; 12:106–109.PubMedGoogle Scholar
  159. 157.
    Aspinwall CA et al. Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca2+ stores in insulin-stimulated insulin secretion in beta-cells. J Biol Chem 2000; 275:22331–22338.PubMedGoogle Scholar
  160. 158.
    Chen WS et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Aktl gene. Genes Dev 2001; 15:2203–2208.PubMedGoogle Scholar
  161. 159.
    Cho H, Thorvaldsen JL, Chu Q et al. Aktl/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001: 276:38349–38352.PubMedGoogle Scholar
  162. 160.
    Kitamura T et al. Preserved pancreatic beta-cell development and function in mice lacking the insulin receptor-related receptor. Mol Cell Biol 2001; 21:5624–5630.PubMedGoogle Scholar
  163. 161.
    Yakar S et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96:7324–7329.PubMedGoogle Scholar
  164. 162.
    Liu JL, Yakar S, LeRoith D. Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology 2000; 141:4436–4441.PubMedGoogle Scholar
  165. 163.
    Yakar S et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50:1110–1118.PubMedGoogle Scholar
  166. 164.
    Devedjian JC et al. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. The Journal of Clinical Investigation 2000; 105:731–740.PubMedGoogle Scholar
  167. 165.
    Moller DE et al. Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose, tolerance, and dyslipidemia. Endocrinology 1996; 137:2397–2405.PubMedGoogle Scholar
  168. 166.
    Bruning JC et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998; 2: 559–569.PubMedGoogle Scholar
  169. 167.
    Mauvais-Jarvis F et al. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes 2000; 49:2126–2134.PubMedGoogle Scholar
  170. 168.
    Bruning JC et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289:2122–2125.PubMedGoogle Scholar
  171. 169.
    Bluher M et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3:25–38.PubMedGoogle Scholar
  172. 170.
    Lauro D, Kido Y, Hayashi H et al. Transgenic knock-out mice with a targeted impairment of insulin action in skeletal muscle and adipose tissue. Diabetes 1998; 47(Supp. 1):A45.Google Scholar
  173. 171.
    Choudhury AI et al. The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 2005; 115:940–950.PubMedGoogle Scholar
  174. 172.
    Fernandez AM et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001; 15:1926–1934.PubMedGoogle Scholar
  175. 173.
    Chen D, Mauvais-Jarvis F, Bluher M et al. p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol Cell Biol 2004; 24:324–329.Google Scholar
  176. 174.
    Kulkarni RN. The islet beta-cell. Int J Biochem Cell Biol 2004; 36(3):365–71.PubMedGoogle Scholar
  177. 175.
    Kulkarni RN. New insights into the roles of Insulin/IGF-I in the development and maintenance of beta-cell mass. Rev Endocr Metab Disord 2005; 6(3):199–210.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Rohit N. Kulkarni
    • 1
    • 2
  1. 1.Division of Cell and Molecular PhysiologyJoslin Diabetes CenterBostonUSA
  2. 2.Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations